Flolan, the first drug to be approved for the treatment of pulmonary arterial hypertension, has been discontinued after 30 years on the market

After 30 years on the market, Flolan (epoprostenol) was discontinued in November 2025, marking the end of an era for pulmonary arterial hypertension treatment. Healthcare professionals worked throughout 2025 to transition patients to alternative therapies. Veletri, a room temperature-stable version of epoprostenol, remains available. A recent article in the News section of the US Pulmonary […]

Flolan, the first drug to be approved for the treatment of pulmonary arterial hypertension, has been discontinued after 30 years on the market Read Post »

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care

Professor Marc Humbert, one of the world’s leading specialists in pulmonary arterial hypertension (PAH), has been awarded the prestigious Inserm Grand Prize in recognition of his extraordinary career dedicated to understanding and treating this life-threatening disease. Inserm is the French National Institute of Health and Medical Research. From Orphan Disease to Hope When Prof. Humbert

Inserm, France’s National Institute of Health and Medical Research, awards its 2025 Grand Prix to Prof. Marc Humbert for his role in transforming pulmonary hypertension care Read Post »

The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026

The Pulmonary Vascular Research Institute (PVRI) Congress 2026 will take place in the historic city of Dublin from 28 January – 1 February 2026. ➡️ Explore the full Congress programme at this link The first and last day (28 January and 1 February) will be satellite meetings with the main plenary sessions happening 29-31 January.

The Pulmonary Vascular Research Institute (PVRI) 2026 Congress is taking place in Dublin from 28 January-1 February 2026 Read Post »

The European Reference Network for Rare Lung Diseases (ERN Lung) to implement universal online Patient-Reported Outcome Measure, ERN-Lung Newsletter, Issue 41, December 2025

Patient-reported outcome measures (PROMs) capture patients’ own perspectives on their health and are crucial for improving care, yet they remain underused in clinical practice due to barriers like time constraints, language availability, and licensing costs. The European Reference Center for Rare Lung Diseases (ERN LUNG) is launching an ambitious initiative to implement a standardized PROM

The European Reference Network for Rare Lung Diseases (ERN Lung) to implement universal online Patient-Reported Outcome Measure, ERN-Lung Newsletter, Issue 41, December 2025 Read Post »

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025

The Pulmonary Vascular Research Institute (PVRI) GoDeep meta-registry integrates data from international pulmonary hypertension registries, from which 21,123 incident hemodynamically fully characterised patients were analysed to investigate the influence of sex on survival of patients. Findings revealed that male patients have significantly higher mortality rates than female patients across all types of pulmonary hypertension. This survival

Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment, EBioMedicine, December 16, 2025 Read Post »

The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants

The Alliance for Pulmonary Hypertension’s quarterly webinars aim to keep the community informed and connected by examining recent advancements, emerging research, and new initiatives in pulmonary hypertension. Through a blend of expert (scientific and patient) presentations and open dialogue, these sessions encourage active participation and create space for diverse perspectives from patients, caregivers, and healthcare

The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants Read Post »

Celebrating the Alliance for Pulmonary Hypertension’s first 18 “PEP Talks” since the launch of the program in May 2025, and looking forward to many more in 2026!

The Alliance for Pulmonary Hypertension introduced its 2025 “Patients Empowering Patients” (PEP) program, designed to harness the power of peer-to-peer support, on May 5, 2025, World Pulmonary Hypertension Day. The name “PEP Talks” is a playful nod to the acronym of the “PEP” program, and it embodies the encouraging and motivational spirit of traditional pep

Celebrating the Alliance for Pulmonary Hypertension’s first 18 “PEP Talks” since the launch of the program in May 2025, and looking forward to many more in 2026! Read Post »

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025 Read Post »

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025 Read Post »

Merck Receives Positive EU CHMP Opinion for Expanded Use of Sotatercept in Adults with Pulmonary Arterial Hypertension, December 12, 2025

The European Medicines Agency’s Committee for Human Medicinal Products (CHMP) has recommended expanding WINREVAIR™ (sotatercept) approval for pulmonary arterial hypertension (PAH) treatment to include World Health Organisation (WHO) Functional Class II, III, and IV patients (previously only II-III). The recommendation is based on the Phase 3 ZENITH trial, which showed a 76% reduction in risk

Merck Receives Positive EU CHMP Opinion for Expanded Use of Sotatercept in Adults with Pulmonary Arterial Hypertension, December 12, 2025 Read Post »

Cereno Scientific receives Food and Drug Administration (FDA) clearance to initiate global Phase IIb clinical trial of CS1 in pulmonary arterial hypertension (PAH), December 8, 2025

The Food and Drug Administration (FDA)’s recent clearance for a Cereno Scientific Phase IIb trial on CS1 builds on the favourable safety, tolerability and encouraging disease-modifying signals observed in the Phase IIa study. CS1, an HDACi that acts through epigenetic modulation, has also been granted Orphan Drug Designation and Fast Track designation in the US. The

Cereno Scientific receives Food and Drug Administration (FDA) clearance to initiate global Phase IIb clinical trial of CS1 in pulmonary arterial hypertension (PAH), December 8, 2025 Read Post »

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue

In an article published in the December 2025 issue of Intelligent Hospital on the challenges of telehealth adoption in rural communities, the authors examine why telehealth uptake remains limited outside urban areas despite its growing role in modern healthcare. The study explains that although technology has transformed health services by improving clinical capabilities and patient

Telehealth in rural areas: Bridging the gaps through policy drivers, Intelligent Hospital, December 2025 issue Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

The Pulmonary Vascular Research Institute (PVRI) launches its Pulmonary Hypertension Patient Engagement & Empowerment Series

The Pulmonary Hypertension Patient Engagement & Empowerment Series is a new evidence-based resource designed to help people living with pulmonary hypertension and their families and carers to be more informed, confident, and empowered. The series was developed by Pulmonary Vascular Research Institute IDDI Patient Engagement & Empowerment Workstream. The series explores 11 core themes, including:

The Pulmonary Vascular Research Institute (PVRI) launches its Pulmonary Hypertension Patient Engagement & Empowerment Series Read Post »

What Do Patients Think About Right Heart Catheterizations? Four patients share what it means to them, Journal of Cardiac Failure, November 21, 2025

Right heart catheterization often marks a turning point in the journey of people living with pulmonary hypertension. Yet an important question remains: what do patients actually experience during this procedure, and what kind of support do they need once it’s over? A paper published recently on the Journal of Cardiac Failure features insights from four

What Do Patients Think About Right Heart Catheterizations? Four patients share what it means to them, Journal of Cardiac Failure, November 21, 2025 Read Post »

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension

Pfizer has a new study ongoing on PF-07868489, a recombinant human IgG1 antibody that targets bone morphogenetic protein 9 (BMP9) and is administered through subcutaneous route for the treatment of PAH. PF-07868489 is currently in Phase 2 development and has received Orphan Drug designation in the US.  The study (NCT06137742) has two parts: Part A: An

PF-07868489: Pfizer’s New Biologic Enters Phase 2 for Pulmonary Arterial Hypertension Read Post »

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025 

A review recently published in the European Respiratory Journal Open Research provides the latest evidence on drug- and toxin-associated pulmonary arterial hypertension, offering clinicians updated guidance on recognition, diagnosis, and management of this pulmonary arterial hypertension subtype (see below for the most recent pulmonary arterial hypertension classification, at 1.3) The first World Health Organization (WHO)

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025  Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

TRANSLATE »
Scroll to Top